IVBT (Innovation1 Biotech) EBIT: $-4.84 Mil (TTM As of Feb. 2024)


IVBT Innovation1 Biotech Inc IVBT
12 GF Score
Price $0.00
View Full Analysis

What is Innovation1 Biotech EBIT?

Innovation1 Biotech IVBT 12 EBIT is $-4.84 Mil as of Feb. 2024. GuruFocus rates IVBT with a GF Score™ of 12/100.

Innovation1 Biotech's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2024 was $-0.15 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2024 was $-4.84 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Innovation1 Biotech's annualized ROC % for the quarter that ended in Feb. 2024 was -1,132.08%. Innovation1 Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -60,000.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Innovation1 Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -949.80%.

Innovation1 Biotech  (OTCPK:IVBT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Innovation1 Biotech's annualized ROC % for the quarter that ended in Feb. 2024 is calculated as:

ROC % (Q: Feb. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2023 ) + Invested Capital (Q: Feb. 2024 ))/ count )
=-0.6 * ( 1 - 0% )/( (0.053 + 0.053)/ 2 )
=-0.6/0.053
=-1,132.08 %

where

Invested Capital(Q: Nov. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.02 - 2.606 - ( 0.006 - max(0, 2.656 - 0.017+0.006))
=0.053

Invested Capital(Q: Feb. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.122 - 2.854 - ( 0.108 - max(0, 2.904 - 0.119+0.108))
=0.053

Note: The Operating Income data used here is four times the quarterly (Feb. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Innovation1 Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2023  Q: Feb. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.6/( ( (0.001 + max(-2.595, 0)) + (0.001 + max(-2.843, 0)) )/ 2 )
=-0.6/( ( 0.001 + 0.001 )/ 2 )
=-0.6/0.001
=-60,000.00 %

where Working Capital is:

Working Capital(Q: Nov. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.011) - (2.606 + 0 + 4.4408920985006E-16)
=-2.595

Working Capital(Q: Feb. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.011) - (2.854 + 0 + 0)
=-2.843

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Innovation1 Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2024 )
=-4.844/0.510
=-949.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation1 Biotech EBIT Related Terms

Innovation1 Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Innovation1 Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation1 Biotech EBIT Chart

Innovation1 Biotech Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
EBIT
Get a 7-Day Free Trial Premium Member Only -0.17 -1.28 1.26 -40.87 -5.74

Innovation1 Biotech Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.57 -0.20 -4.34 -0.15 -0.15

IVBT vs NVIV, PXMD, SCNI: EBIT Comparison

For the Shell Companies subindustry, Innovation1 Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation1 Biotech EV-to-EBIT vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Innovation1 Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Innovation1 Biotech's EV-to-EBIT falls into.


IVBT
12GF Score
Innovation1 Biotech Inc IVBT
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovation1 Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-4.84 Mil mean?
Innovation1 Biotech (IVBT) has a EBIT of $-4.84 Mil as of Feb. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Innovation1 Biotech.
Is Innovation1 Biotech's EBIT too high?
Innovation1 Biotech's current EBIT is $-4.84 Mil. Overall, Innovation1 Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Innovation1 Biotech's EBIT compare to NVIV and PXMD?
Innovation1 Biotech's EBIT of $-4.84 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Diversified Financial Services company?
A good EBIT depends on the Diversified Financial Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Innovation1 Biotech. Innovation1 Biotech's current EBIT is $-4.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation1 Biotech stock overvalued right now?
Innovation1 Biotech (IVBT) has a current EBIT of $-4.84 Mil. The current EBIT is $-4.84 Mil. Innovation1 Biotech's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Innovation1 Biotech (IVBT), the current EBIT is $-4.84 Mil as of Feb. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation1 Biotech Business Description

Address 7 Grand View Avenue, Somerville, MA, USA, 02143
Innovation1 Biotech Inc is a shell company.
12GF Score

Get the complete analysis for IVBT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price